Experimental peanut allergy patch shows promise

November 15, 2017
peanuts
Credit: Daniele Pellati/public domain

An experimental patch that delivers a high dose of peanut protein has shown promise in reducing allergic reactions in children and adults, researchers said on Tuesday.

About two percent of US children are allergic to peanuts and must avoid them altogether.

Peanut allergies are on the rise, and are the most common cause of severe and fatal food reactions in the United States, according to researchers.

The study published in the Journal of the American Medical Association (JAMA) enrolled 221 children and adults who are allergic to peanuts.

Participants were randomly assigned to three groups, each of which wore a Viaskin Peanut skin patch in different doses. A fourth group received a placebo.

The trial, known as phase two, was designed to test which dose was best, and how well it would work over a year.

The highest dose tested, 250 micrograms, was most effective, and appeared to help half the patients who wore it. The placebo patch helped one-quarter of wearers.

Patients were considered "responders" if they took without incident either 1,000 mg or more of , or 10 times the pretreatment amount of peanuts.

But since there were only 28 patients in the 250-microgram patch group, a larger study is needed to better understand how well the patch might work.

"The sample size of each treatment group was relatively small," said the study led by Hugh Sampson of the Icahn School of Medicine at Mount Sinai, New York.

A further trial—known as phase three and which aims to flesh out more widely how the patch works—has been initiated in children aged four to 11 using the 250-microgram patch, according to the report.

In January, the National Institute of Allergy and Infectious Diseases (NIAID) urged parents to feed babies -containing foods beginning at the age of four months to five years.

This practice reduces by 81 percent the risk of among infants deemed at high risk because they already had severe eczema, egg allergy or both, the agency said.

Explore further: Skin patch shows promise in easing peanut allergy

More information: Hugh A. Sampson et al. Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity, JAMA (2017). DOI: 10.1001/jama.2017.16591

Related Stories

Skin patch shows promise in easing peanut allergy

February 23, 2015
A wearable patch that safely and gradually exposes the body to small amounts of peanut allergen appears effective in easing the allergy, an early new study shows.

Study suggests patch is safe, convenient mode of treatment for peanut allergy

October 26, 2016
A wearable patch that delivers small amounts of peanut protein through the skin shows promise for treating children and young adults with peanut allergy, with greater benefits for younger children, according to one-year results ...

New study suggests 21 percent increase in childhood peanut allergy since 2010

October 27, 2017
Parents often worry about peanut allergies because the reaction to peanuts can be very severe. New late-breaking research being presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific ...

Study suggests women eating peanuts during breastfeeding could prevent child from developing allergy

October 2, 2017
(Medical Xpress)—A team of researchers with members from several institutions in Canada has conducted a study on women eating peanuts while breastfeeding and has found evidence that suggests doing so can reduce the chances ...

Patch to treat peanut allergies to get expedited FDA review

April 14, 2015
A medical skin patch tested by Seattle-area doctors and families to treat dangerous peanut allergies in children will receive accelerated regulatory review, officials said Thursday.

Oral immunotherapy is safe, effective for peanut-allergic preschoolers, study suggests

August 10, 2016
Nearly 80 percent of peanut-allergic preschool children successfully incorporated peanut-containing foods into their diets after receiving peanut oral immunotherapy (OIT), a clinical trial has found. Peanut OIT involves eating ...

Recommended for you

Study explores whole-body immunity

November 21, 2017
Over the next few months, millions of people will receive vaccinations in the hope of staving off the flu—and the fever, pain, and congestion that come with it.

Drug could cut transplant rejection

November 21, 2017
A diabetes drug currently undergoing development could be repurposed to help end transplant rejection, without the side-effects of current immunosuppressive drugs, according to new research by Queen Mary University of London ...

Atopic eczema—one size does not fit all

November 21, 2017
Researchers from the UK and Netherlands have identified five distinct subgroups of eczema, a finding that helps explain how the condition can affect people at different stages of their lives.

Breast milk found to protect against food allergy

November 20, 2017
Eating allergenic foods during pregnancy can protect your child from food allergies, especially if you breastfeed, suggests new research from Boston Children's Hospital. The study, published online today in the Journal of ...

Zika-related nerve damage caused by immune response to the virus

November 20, 2017
The immune system's response to the Zika virus, rather than the virus itself, may be responsible for nerve-related complications of infection, according to a Yale study. This insight could lead to new ways of treating patients ...

How a poorly explored immune cell may impact cancer immunity and immunotherapy

November 17, 2017
The immune cells that are trained to fight off the body's invaders can become defective. It's what allows cancer to develop. So most research has targeted these co-called effector T-cells.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.